Survival rates of biological therapies for psoriasis treatment in real‐world clinical practice: A Canadian multicentre retrospective study. (12th November 2016)

• Record Type: Journal Article
• Authors: Marinas, Joseph EC; Kim, Whan B; Shahbaz, Ali; Qiang, Judy K; Greaves, Simon; Yeung, Jensen
• Is Part Of: Australasian journal of dermatology. Volume 59:Number 1(2018)
• Page Start: e11
• Page End: e14
• Publication Date: 2016-11-12
• Subjects: biological -- drug survival -- plaque psoriasis; Dermatology -- Periodicals; Dermatology -- Australasia -- Periodicals; 616.5005
• DOI: 10.1111/ajd.12548
• Languages: English
• ISSNs: 0004-8380

Abstract

Abstract: Background/Objectives: Data on biologic drug survival in real‐world psoriasis treatment are limited. There is a need to evaluate long‐term trends of biologic use outside the realm of clinical trials. Methods: A multicentre chart review was conducted with patients' data from September 2005 to September 2014. Kaplan–Meier plot analysis was used to determine 5‐year drug survival rates. A log–rank test was used to compare the rates of drug survival between the studied biologics. Results: For the 398 patients and 545 treatment series analysed, 1, 2, 3, 4 and 5‐year survival rates were 0.826, 0.687, 0.563, 0.475 and 0.420 with etanercept; 0.804, 0.648, 0.553, 0.508 and 0.508 with adalimumab; 0.838, 0.664, 0.554, 0.485 and 0.382 with infliximab; and 0.914, 0.856, 0.800, 0.755 and 0.755 with ustekinumab, respectively. A statistically significant difference was seen between ustekinumab and the other three biologics. Conclusion: A progressive decrease in treatment adherence was seen with all four biologics, as expected, but the survival rate of ustekinumab was highest.